Nuvectis Pharma, Inc. (NVCT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 11, 2026, details the results of Nuvectis Pharma, Inc.'s 2026 Annual Meeting of Stockholders. The meeting was held online on June 11, 2026. The filing also addresses a correction regarding the number of shares outstanding previously reported in the Company's Definitive Proxy Statement filed on April 27, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Share Count Correction: The Company corrected the total number of common stock shares outstanding as of the record date (April 13, 2026). The previously stated figure of 27,668,036 was incorrect; the accurate number is 26,614,628. The Company confirmed this correction does not affect the validity of the votes or the outcome of the proposals.
Quorum and Participation: Stockholders representing 16,193,686 shares (60.8% of the outstanding shares) were present, establishing a quorum.
Proposal Outcomes: All proposals were approved.
- Proposal 1 (Election of Class I Director): Ron Bentsur was elected with 8,354,838 votes for, 391,265 votes against, and 216 abstentions. There were 7,447,367 broker non-votes.
- Proposal 2 (Ratification of Auditors): Kesselman & Kesselman was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 15,662,222 votes for, 10,574 votes against, and 520,890 abstentions.
Guidance, Outlook, and Risks
The filing text does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items beyond the administrative correction of the share count.
Investor Verification Checklist
- Verify the corrected share count of 26,614,628 as of April 13, 2026, in subsequent filings.
- Confirm the re-election of Ron Bentsur as a Class I director serving until the 2029 annual meeting.
- Review the full Definitive Proxy Statement (Schedule 14A) filed on April 27, 2026, for detailed descriptions of the proposals.
- Note that the Company is classified as an emerging growth company.